Skip to main content

Amylin analogs

07-14-2023 | Type 2 diabetes | News

Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes

Improved glycemic control and weight loss seen with the coadministration of cagrilintide and semaglutide in a phase 2 trial.

11-26-2021 | Cagrilintide | News

Promising phase 2 results for long-acting amylin analog cagrilintide

The long-acting amylin analog cagrilintide promotes notable weight loss during 26 weeks of use, show phase 2 trial findings.

10-08-2021 | Artificial pancreas systems | News

Fully closed-loop insulin delivery not yet a match for precise carb counting

A dual-hormone fully closed-loop system did not demonstrate non-inferiority to a hybrid system in a randomized trial, despite producing a high time in range, report the researchers.

06-28-2021 | ADA 2021 | Conference coverage | News

Pramlintide, prandial insulin co-formulation gives benefits of both in one injection

A co-formulation of pramlintide and a prandial insulin offers improved postprandial glucose control and weight loss, without an increased number of injections, show the results of a small crossover trial.

Weight loss concept

05-04-2021 | Obesity | News

Cagrilintide, semaglutide combination warrants further investigation for weight loss

Phase 1 trial results published in The Lancet suggest that combination treatment with the long-acting amylin analog cagrilintide plus high-dose semaglutide is well tolerated and may be a feasible treatment option for obesity.

09-25-2020 | EASD 2020 | Conference coverage | News

Fully closed-loop insulin delivery edges closer with pramlintide–faster aspart system

A fully automated dual-hormone delivery system with pramlintide and faster-acting insulin aspart delivers overall glycemic control that is nearly as good as that achieved with a hybrid closed-loop system with the insulin only, report researchers at the virtual 56th EASD Annual Meeting.